preservation strategies, and anti-aging pathways.
Product Specifications:

Contents: NA-931 (PROYU-931) [IGF-1 modified peptide]
Size: 10mg
Form: Lyophilized powder
Purity: >99.8%

Product Overview
Mechanism of Action & Quadruple-Agonist Design
NA-931 utilizes a novel poly-agonist approach to modulate four distinct yet interrelated pathways involved in metabolism and tissue homeostasis:

Incretin Receptor Activation (GLP-1 & GIP): NA-931 activates both GLP-1 and GIP receptors. GLP-1 activation slows gastric emptying and enhances satiety via central nervous system

pathways. GIP activation enhances nutrient-stimulated insulin secretion and modulates adipose tissue metabolism, potentially mitigating gastrointestinal side effects often associated with isolated GLP-1 agonism.
Glucagon Receptor Activation: By targeting the glucagon receptor, NA-931 aims to increase energy expenditure, promote lipid mobilization, and potentially reduce intrahepatic fat accumulation, distinct from the mechanisms of single or dual incretin agonists.
IGF-1 Receptor Modulation: A critical and unique feature of NA-931 is its modified interaction with the IGF-1 receptor. This component is designed to investigate broad-spectrum tissue homeostasis and potential anti-aging effects, with a specific focus on muscle mass preservation—a major area of research in comprehensive weight management and metabolic health models.

Research and Preclinical Data Summary

Metabolic and Obesity Research: The multi-agonist profile of NA-931 is currently under evaluation for the treatment of general obesity and cardiometabolic health. Preclinical models have demonstrated significant improvements in various metabolic parameters and a sustained duration of action.
Muscle Preservation & Tissue Homeostasis: Through its IGF-1 modulatory component, NA-931 is being investigated for its potential to preserve muscle mass. Research is focused on assessing its capability to maintain muscle-preservation models during periods of significant metabolic regulation or caloric restriction.

Safety, Advisories, and Research Status

Clinical Investigation: NA-931 (PROYU-931) is currently an investigational agent. A Clinical Phase 1 study has been initiated to formally evaluate its safety and pharmacokinetics in humans.
Regulatory Status: NA-931 is not approved by the FDA, EMA, MHRA, or any other regulatory body for human or veterinary administration outside of strictly authorized clinical research protocols.

Important Notice
This product is provided strictly for laboratory research, analytical testing, and preclinical experimentation by qualified scientific professionals. It is not intended, nor approved, for human or veterinary administration, diagnostic protocols, or therapeutic applications. All research must be conducted in

compliance with applicable ethical and institutional guidelines.